LV12638A - Enteric coated pharmaceutical tablet and method of manufacturing - Google Patents

Enteric coated pharmaceutical tablet and method of manufacturing

Info

Publication number
LV12638A
LV12638A LV010019A LV010019A LV12638A LV 12638 A LV12638 A LV 12638A LV 010019 A LV010019 A LV 010019A LV 010019 A LV010019 A LV 010019A LV 12638 A LV12638 A LV 12638A
Authority
LV
Latvia
Prior art keywords
manufacturing
enteric coated
pharmaceutical tablet
coated pharmaceutical
tablet
Prior art date
Application number
LV010019A
Other languages
English (en)
Other versions
LV12638B (lv
Inventor
Ismat Ullah
Gary J Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LV12638A publication Critical patent/LV12638A/lv
Publication of LV12638B publication Critical patent/LV12638B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
LV010019A 1998-07-17 2001-02-12 Ar zarnas skistosu apvalku parklata tablete un tas iegusanas panemiens LV12638B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11841898A 1998-07-17 1998-07-17
PCT/US1998/016323 WO2000003696A1 (en) 1998-07-17 1998-08-06 Enteric coated pharmaceutical tablet and method of manufacturing

Publications (2)

Publication Number Publication Date
LV12638A true LV12638A (lv) 2001-04-20
LV12638B LV12638B (lv) 2001-09-20

Family

ID=22378467

Family Applications (1)

Application Number Title Priority Date Filing Date
LV010019A LV12638B (lv) 1998-07-17 2001-02-12 Ar zarnas skistosu apvalku parklata tablete un tas iegusanas panemiens

Country Status (35)

Country Link
US (2) US6331316B1 (lv)
EP (1) EP1098635B1 (lv)
JP (1) JP2002520350A (lv)
KR (1) KR100535954B1 (lv)
CN (1) CN1195499C (lv)
AR (1) AR019934A1 (lv)
AT (1) ATE268165T1 (lv)
AU (1) AU750388B2 (lv)
BG (1) BG65443B1 (lv)
BR (1) BR9815948A (lv)
CA (1) CA2337885C (lv)
CO (1) CO5090840A1 (lv)
CZ (1) CZ301557B6 (lv)
DE (1) DE69824319T2 (lv)
DK (1) DK1098635T3 (lv)
EE (1) EE05021B1 (lv)
EG (1) EG23944A (lv)
ES (1) ES2221188T3 (lv)
GE (1) GEP20032912B (lv)
HU (1) HU226492B1 (lv)
ID (1) ID27019A (lv)
IL (1) IL139701A0 (lv)
LT (1) LT4844B (lv)
LV (1) LV12638B (lv)
NO (1) NO330554B1 (lv)
NZ (1) NZ508298A (lv)
PL (1) PL195587B1 (lv)
PT (1) PT1098635E (lv)
RO (1) RO121082B1 (lv)
RU (1) RU2201217C2 (lv)
SK (1) SK285152B6 (lv)
TR (1) TR200003577T2 (lv)
UA (1) UA73092C2 (lv)
WO (1) WO2000003696A1 (lv)
ZA (1) ZA993446B (lv)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6756811B2 (en) * 2000-03-10 2004-06-29 Easic Corporation Customizable and programmable cell array
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
GB2379854B (en) * 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
JP2005535558A (ja) 2001-09-28 2005-11-24 マクニール−ピーピーシー・インコーポレイテッド 改質した放出用の投薬形態
US20030190350A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
US6967218B2 (en) * 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
MXPA05002095A (es) * 2002-09-03 2005-06-06 Biovail Lab Int Srl Formulaciones farmaceuticas de pravastatina y metodos de su uso.
EP1545474A1 (en) * 2002-09-16 2005-06-29 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
WO2004030658A1 (en) 2002-10-01 2004-04-15 Banner Pharmacaps, Inc. Enteric composition for the manufacture of soft capsule wall
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
WO2005065291A2 (en) * 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
CA2554771A1 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
JP2007530492A (ja) * 2004-03-26 2007-11-01 レツク・フアーマシユーテイカルズ・デー・デー Ｎ−（２−（２−フタルイミドエトキシ）−アセチル）−ｌ−アラニル−ｄ−グルタミン酸（ｌｋ−４２３）を含む胃耐性の医薬品投薬形態物
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP2803357B1 (en) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
WO2006054175A2 (en) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Stable dosage forms of acid labile drug
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
MX2007007836A (es) * 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
CN100398122C (zh) * 2005-01-28 2008-07-02 北京北大药业有限公司 一种治疗颈、腰椎病中药的肠溶包衣组合物
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
EP2324886A1 (en) 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Novel deuterated analogues of tadalafil
AU2005334837B2 (en) 2005-07-29 2012-07-19 Stichting Groningen Centre For Drug Research PH-controlled pulsatile delivery system, methods for preparation and use thereof
CA2617150C (en) * 2005-07-29 2016-06-14 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
LT2535044T (lt) 2006-01-27 2020-04-10 The Regents Of The University Of California Enteriškai dengtas cisteamino bitartratas ir cistaminas
CA2645988C (en) 2006-03-17 2017-01-10 John P. Toscano N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2008015686A1 (en) * 2006-08-01 2008-02-07 Hetero Drugs Limited Stable multiparticulate formulations of didanosine
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
US8551995B2 (en) 2007-01-19 2013-10-08 Xcovery Holding Company, Llc Kinase inhibitor compounds
KR20100092928A (ko) * 2007-09-26 2010-08-23 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 ｎ-히드록실술폰아미드 유도체
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
TWI592159B (zh) * 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
EP2636404B1 (en) 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
CN104945309B (zh) 2008-05-07 2019-06-04 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其用途
US20090317466A1 (en) * 2008-06-18 2009-12-24 Franco Lori Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine
JP5670325B2 (ja) 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20110165248A1 (en) * 2008-09-18 2011-07-07 Meridith Lee Machonis Pharmaceutical dosage forms comprising poly(e-caprolactone)
US8729097B2 (en) 2008-10-06 2014-05-20 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
KR20110124780A (ko) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
US8785160B2 (en) * 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
JP5592902B2 (ja) 2009-03-09 2014-09-17 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 治療薬の徐放性組成物
SG174291A1 (en) * 2009-03-13 2011-10-28 Toyama Chemical Co Ltd Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
AU2010328234B2 (en) 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
US9018411B2 (en) 2009-12-07 2015-04-28 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
PL2625176T3 (pl) 2010-10-08 2017-08-31 Xcovery Holding Company Llc Podstawione związki 6-amino-pirydazyn-3-ylo-karboksyamidu jako modulatory kinazy białkowej
US20130084313A1 (en) * 2011-09-30 2013-04-04 Stomavite, Llc Supplement for ostomy patients
KR102061537B1 (ko) 2011-10-17 2020-01-03 더 존스 홉킨스 유니버시티 Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片
CN102526746B (zh) * 2012-02-04 2013-09-18 安徽山河药用辅料股份有限公司 肠溶型水分散体包衣材料的制备方法
US9676708B2 (en) 2012-11-01 2017-06-13 The Johns Hopkins University Controlled HNO release through intramolecular cyclization-elimination
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
ES2882279T3 (es) 2013-01-18 2021-12-01 Cardioxyl Pharmaceuticals Inc Composiciones farmacéuticas que comprenden donadores de nitroxilo
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US20170216328A1 (en) 2014-04-04 2017-08-03 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015195989A1 (en) 2014-06-20 2015-12-23 Banner Life Sciences Llc Enteric soft capsule compositions
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
US10202363B2 (en) 2014-12-23 2019-02-12 Cerecor, Inc. Compounds, compositions and methods
RU2668499C2 (ru) * 2015-03-12 2018-10-01 Закрытое Акционерное Общество "Фармфирма "Сотекс" Фармацевтическая композиция в форме таблеток, покрытых кишечнорастворимой оболочкой, и способ ее получения
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
AU2016276783B2 (en) 2015-06-09 2020-07-02 Rexahn Pharmaceuticals, Inc. Fluorocyclopentenylcytosine uses and processes of preparation
WO2017040980A2 (en) 2015-09-04 2017-03-09 Rexahn Pharmaceuticals, Inc. Quinoxalinyl-piperazinamide methods of use
EP3370748B1 (en) 2015-11-03 2022-06-08 The Brigham and Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2017191501A2 (en) 2016-05-04 2017-11-09 D'oosterlynck André Simmondsin formulation
WO2018067422A1 (en) 2016-10-03 2018-04-12 Congxin Liang Novel jak1 selective inhibitors and uses thereof
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
JP2021522308A (ja) 2018-05-04 2021-08-30 トゥリーズ 上皮細胞及び骨髄細胞の両方を活性化するｔｌｒ３リガンド
FR3083545A1 (fr) 2018-07-04 2020-01-10 Institut National De La Recherche Agronomique Utilisation d'une souche de roseburia intestinalis pour la prevention et le traitement de l'inflammation de l'intestin
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020096992A1 (en) 2018-11-05 2020-05-14 MarvelBiome, Inc. Microbial compositions comprising ellagitannin and methods of use
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020212822A1 (en) * 2019-04-17 2020-10-22 Amruth Gowda Doddaveerappa Multi-component pharmaceutical single dosage forms and process employed thereof
US20220202818A1 (en) 2019-04-18 2022-06-30 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
WO2020257722A2 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
CN110882228A (zh) * 2019-11-29 2020-03-17 南京禾瀚医药科技有限公司 一种伊匹乌肽肠溶制剂
EP4158014A2 (en) 2020-05-26 2023-04-05 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
WO2021248093A1 (en) 2020-06-05 2021-12-09 Henry Ford Health System Daclatasvir for use in treating lung and prostate cancer
IL303965A (en) 2020-12-22 2023-08-01 Mekanistic Therapeutics Llc Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
WO2023016321A1 (zh) 2021-08-10 2023-02-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4432996A (en) 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8512330D0 (en) 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
JPS62501712A (ja) 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
PH30058A (en) * 1989-11-24 1996-11-08 Biochemie Gmbh Pancreation preparations
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
SK59493A3 (en) * 1990-12-21 1993-11-10 Richardson Vicks Inc Polyamine drug-resin complexes
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
SG42869A1 (en) 1992-08-05 1997-10-17 Faulding F H & Co Ltd Pelletised pharmaceutical composition
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
WO1999027917A1 (de) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції

Also Published As

Publication number Publication date
DK1098635T3 (da) 2004-08-09
WO2000003696A1 (en) 2000-01-27
ZA993446B (en) 2000-11-20
AU8898398A (en) 2000-02-07
CA2337885A1 (en) 2000-01-27
NO20010260D0 (no) 2001-01-16
NO20010260L (no) 2001-03-07
EG23944A (en) 2008-01-22
BR9815948A (pt) 2001-02-28
US6569457B2 (en) 2003-05-27
AR019934A1 (es) 2002-03-27
CA2337885C (en) 2008-01-08
LT2001003A (en) 2001-06-25
EE200100033A (et) 2002-06-17
US20020051818A1 (en) 2002-05-02
CO5090840A1 (es) 2001-10-30
EP1098635A4 (en) 2002-01-16
HUP0102659A2 (hu) 2002-03-28
US6331316B1 (en) 2001-12-18
CZ2001215A3 (cs) 2001-10-17
ID27019A (id) 2001-02-22
GEP20032912B (en) 2003-03-25
KR100535954B1 (ko) 2005-12-12
LV12638B (lv) 2001-09-20
DE69824319T2 (de) 2005-08-04
RU2201217C2 (ru) 2003-03-27
LT4844B (lt) 2001-09-25
TR200003577T2 (tr) 2001-06-21
EE05021B1 (et) 2008-06-16
BG65443B1 (bg) 2008-08-29
BG105203A (bg) 2001-09-28
UA73092C2 (uk) 2005-06-15
EP1098635A1 (en) 2001-05-16
PL195587B1 (pl) 2007-10-31
KR20010070981A (ko) 2001-07-28
IL139701A0 (en) 2002-02-10
PT1098635E (pt) 2004-09-30
AU750388B2 (en) 2002-07-18
CZ301557B6 (cs) 2010-04-14
CN1195499C (zh) 2005-04-06
SK285152B6 (sk) 2006-07-07
DE69824319D1 (de) 2004-07-08
HU226492B1 (en) 2009-03-02
SK18832000A3 (sk) 2002-01-07
HUP0102659A3 (en) 2002-12-28
EP1098635B1 (en) 2004-06-02
NO330554B1 (no) 2011-05-16
ATE268165T1 (de) 2004-06-15
JP2002520350A (ja) 2002-07-09
PL345774A1 (en) 2002-01-02
CN1338925A (zh) 2002-03-06
NZ508298A (en) 2003-11-28
RO121082B1 (ro) 2006-12-29
ES2221188T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
LV12638A (lv) Enteric coated pharmaceutical tablet and method of manufacturing
HUP0101714A3 (en) Enteric coated pharmaceutical composition and method of manufacturing
NO20021931D0 (no) L-pantolacton-hydrolase og en fremgangsmåte for fremstilling av D-pantolacton
IS5245A (is) Lyfjablanda úr ómeprasól
NO20000932D0 (no) Farmasøytisk preparat for kombinasjon av piperidinoalkanol og dekongestant
DK1041879T4 (da) Desinfektionsmiddel og fremstillingsmetode
DE60025536D1 (de) Beschichtung von tablettenkernen
DE69616057D1 (de) Umhülltes retroreflektierendes element und herstellungsverfahren
ID23638A (id) Metode pembuatan ekstrak artemisia farmasi dan peralatan untuk moksibusi listik menggunakan ekstrak tersebut
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
EE04154B1 (et) Omeprasooli valmistamise meetod
FR2774910B1 (fr) Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
DE69937596D1 (de) Verbinder und dessen Herstellungsverfahren
NO993034D0 (no) Bjelke og fremgangsmÕte ved fremstilling av samme
EE03248B1 (et) Hüdroksüpropüülmetüültselluloosi sisaldava kattega ranitidiinitablett ja nimetatud katte saamise protsess
UA25519A (uk) Спосіб іhтракаротидhого введеhhя лікарських препаратів
FI990744A0 (fi) Lyhytviipymäpäällystin ja lyhytviipymäpällystysmenetelmä
DK1014951T3 (da) Farmaceutisk coatingssammensætning og fremgangsmåde til anvendelse
SE9702734D0 (sv) Stamper and method of manufacturing the same
SE9803024D0 (sv) Method of manufacturing medical devices
DE69832583D1 (de) Plasma anzeige und herstellungsverfahren derselben
PL326434A1 (en) Pharmaceutical composition and method of manufacturing of the pharmaceutical composition
UA25601A (uk) Коhструкція кhижково-журhальhої обкладиhки і спосіб її виготовлеhhя